Brian L Mark

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 11

Top Venues

Antimicrobial agents and chemotherapy

PLoS pathogens

Acta crystallographica. Section D, Structural biology

Chemical communications (Cambridge, England)

University of Manitoba

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Manitoba Apr 02 2005

Canada

Associate Professor :: Microbiology, Biochemistry & Medical Genetics

Publications

Gabriel Cabot, Ki-Hun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 67 (2) (2023)
Gabriel Cabot, Ki-Hun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 67 (2) (2023)
Gabriel Cabot, Ki-Hun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy (2023)
Gabriel Cabot, Ki-Hun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 67 (2) (2023)
Gabriel Cabot, Ki-Hun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 67 (2) (2023)
Gabriel Cabot, Ki-Hun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 67 (2) (2023)
Gabriel Cabot, Ki-Hun Kim, Brian L Mark, Antonio Oliver, Mazdak Khajehpour
Biochemical Insights into Imipenem Collateral Susceptibility Driven by ampC Mutations Conferring Ceftolozane/Tazobactam Resistance in Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy 67 (2) (2023)
Ben A Bailey-Elkin, Robert C M Knaap, Anuradha De Silva, Ilse M Boekhoud, Sandra Mous, Niek van Vught, Mazdak Khajehpour, Erwin van den Born, Marjolein Kikkert, Brian L Mark
Demonstrating the importance of porcine reproductive and respiratory syndrome virus papain-like protease 2 deubiquitinating activity in viral replication by structure-guided mutagenesis. PLoS pathogens 19 (12) (2023)
MacLean G Kohlmeier, Ben A Bailey-Elkin, Brian L Mark, Ivan J Oresnik
Characterization of the sorbitol dehydrogenase SmoS from Sinorhizobium meliloti 1021. Acta crystallographica. Section D, Structural biology 77 (Pt 3) (2021)
Cole L Slater, Judith Winogrodzki, Pablo A Fraile-Ribot, Antonio Oliver, Mazdak Khajehpour, Brian L Mark
Adding Insult to Injury: Mechanistic Basis for How AmpC Mutations Allow Pseudomonas aeruginosa To Accelerate Cephalosporin Hydrolysis and Evade Avibactam. Antimicrobial agents and chemotherapy 64 (9) (2020)
Louisa A Ho, Judith L Winogrodzki, Aleksandra W Debowski, Zarina Madden, David J Vocadlo, Brian L Mark, Keith A Stubbs
A mechanism-based GlcNAc-inspired cyclophellitol inactivator of the peptidoglycan recycling enzyme NagZ reverses resistance to β-lactams in Pseudomonas aeruginosa. Chemical communications (Cambridge, England) 54 (75) (2018)

Brian L Mark.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Brian L Mark